Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin/Metformin FDC vs co-administered therapy in Chinese T2DM patients
NCT06327815Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by AstraZeneca. Primary endpoint: Glycated Hemoglobin at 24 weeks. Started Mar 2024; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06327815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06327815.